NCT07592481Not yet recruiting
Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase inhibitors (cBTKi). The objective is to determine whether digital BP monitoring improves early detection and management of BTKi-induced hypertension over 6 months.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 5 May 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Centre Hospitalier de la côte Basque
- Diseases
- Follicular lymphoma, Mantle cell lymphoma, High blood pressure, Chronic lymphocytic leukaemia
- NCT number
- NCT07592481
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Jul 2026 to the primary completion date, 31 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known cognitive impairment
Other
- No internet access
- Individuals under guardianship, curatorship, or legal protection
Who the study is looking for
- Age ≥18 years
- Diagnosis of lymphoid malignancy: chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, or mantle cell lymphoma
- Initiation of oral BTK inhibitor therapy (ibrutinib, acalabrutinib, or zanubrutinib), in treatment-naive or relapsed patients
- Affiliation with a social security system
- Signed written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.